Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synosia appoints new VP of neuropharmacology

This article was originally published in Scrip

Executive Summary

Synosia Therapeutics (Switzerland) has appointed Dr Hans-Rudolf Olpe vice-president of neuropharmacology. Dr Olpe has more than 35 years' experience working in neuropharmacology and neurobiology. At Ciba, he served as head of the nervous system pharmacology department and subsequently head of the stroke and epilepsy department at Novartis, where his team developed rufinamide, one of the compounds now in the Synosia portfolio, and the seizure medication Trileptal.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC001515

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel